Compile Data Set for Download or QSAR
Report error Found 50 Enz. Inhib. hit(s) with all data for entry = 11055
TargetFibroblast growth factor receptor 4(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM588120(US11542247, Compound 9)
Affinity DataKd:  191nMAssay Description:FGFR4: In a final reaction volume of 30 μL, FGFR4 (h) (60 ng/ml) is incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 2(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM588117(US11542247, Compound 6)
Affinity DataKd: >3.02E+3nMAssay Description:FGFR2: In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) is incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.0...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 3(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM588117(US11542247, Compound 6)
Affinity DataKd: >3.02E+3nMAssay Description:FGFR3: In a final reaction volume of 30 uL, FGFR3 (h) (40 ng/ml) is incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 4(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM588117(US11542247, Compound 6)
Affinity DataKd: >3.02E+3nMAssay Description:FGFR4: In a final reaction volume of 30 μL, FGFR4 (h) (60 ng/ml) is incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM588117(US11542247, Compound 6)
Affinity DataKd: >3.02E+3nMAssay Description:KDR (VEGFR2): In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) is incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM588119(US11542247, Compound 7)
Affinity DataKd: >3.02E+3nMAssay Description:FGFR1: In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) is incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 2(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM588119(US11542247, Compound 7)
Affinity DataKd: >1.00E+3nMAssay Description:FGFR2: In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) is incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.0...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 3(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM588119(US11542247, Compound 7)
Affinity DataKd: >3.02E+3nMAssay Description:FGFR3: In a final reaction volume of 30 uL, FGFR3 (h) (40 ng/ml) is incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 4(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM588119(US11542247, Compound 7)
Affinity DataKd: >3.02E+3nMAssay Description:FGFR4: In a final reaction volume of 30 μL, FGFR4 (h) (60 ng/ml) is incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM588119(US11542247, Compound 7)
Affinity DataKd:  269nMAssay Description:KDR (VEGFR2): In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) is incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM588120(US11542247, Compound 9)
Affinity DataKd:  141nMAssay Description:FGFR1: In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) is incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 2(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM588120(US11542247, Compound 9)
Affinity DataKd:  933nMAssay Description:FGFR2: In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) is incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.0...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 3(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM588120(US11542247, Compound 9)
Affinity DataKd:  295nMAssay Description:FGFR3: In a final reaction volume of 30 uL, FGFR3 (h) (40 ng/ml) is incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM588117(US11542247, Compound 6)
Affinity DataKd: >3.02E+3nMAssay Description:FGFR1: In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) is incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM588120(US11542247, Compound 9)
Affinity DataKd:  1.05E+3nMAssay Description:KDR (VEGFR2): In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) is incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM588121(US11542247, Compound 11)
Affinity DataKd: >3.02E+3nMAssay Description:FGFR1: In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) is incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 2(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM588121(US11542247, Compound 11)
Affinity DataKd: >3.02E+3nMAssay Description:FGFR2: In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) is incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.0...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 3(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM588121(US11542247, Compound 11)
Affinity DataKd: >3.02E+3nMAssay Description:FGFR3: In a final reaction volume of 30 uL, FGFR3 (h) (40 ng/ml) is incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 4(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM588121(US11542247, Compound 11)
Affinity DataKd: >3.02E+3nMAssay Description:FGFR4: In a final reaction volume of 30 μL, FGFR4 (h) (60 ng/ml) is incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM588121(US11542247, Compound 11)
Affinity DataKd: >3.02E+3nMAssay Description:KDR (VEGFR2): In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) is incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM588122(US11542247, Compound 12)
Affinity DataKd:  1.59E+3nMAssay Description:FGFR1: In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) is incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 2(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM588122(US11542247, Compound 12)
Affinity DataKd:  1.86E+3nMAssay Description:FGFR2: In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) is incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.0...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 3(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM588122(US11542247, Compound 12)
Affinity DataKd:  2.04E+3nMAssay Description:FGFR3: In a final reaction volume of 30 uL, FGFR3 (h) (40 ng/ml) is incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 4(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM588122(US11542247, Compound 12)
Affinity DataKd: >3.02E+3nMAssay Description:FGFR4: In a final reaction volume of 30 μL, FGFR4 (h) (60 ng/ml) is incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM588122(US11542247, Compound 12)
Affinity DataKd: >3.02E+3nMAssay Description:KDR (VEGFR2): In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) is incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 4(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM588101(US11542247, Compound 3)
Affinity DataKd:  1.38E+3nMAssay Description:FGFR4: In a final reaction volume of 30 μL, FGFR4 (h) (60 ng/ml) is incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 2(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM588098(US11542247, Compound 1)
Affinity DataKd:  1.86E+3nMAssay Description:FGFR2: In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) is incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.0...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 3(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM588098(US11542247, Compound 1)
Affinity DataKd:  1.29E+3nMAssay Description:FGFR3: In a final reaction volume of 30 uL, FGFR3 (h) (40 ng/ml) is incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 4(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM588098(US11542247, Compound 1)
Affinity DataKd:  2.46E+3nMAssay Description:FGFR4: In a final reaction volume of 30 μL, FGFR4 (h) (60 ng/ml) is incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM588098(US11542247, Compound 1)
Affinity DataKd: >3.02E+3nMAssay Description:KDR (VEGFR2): In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) is incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM588100(US11542247, Compound 2)
Affinity DataKd:  1.15E+3nMAssay Description:FGFR1: In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) is incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 2(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM588100(US11542247, Compound 2)
Affinity DataKd: >3.02E+3nMAssay Description:FGFR2: In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) is incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.0...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 3(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM588100(US11542247, Compound 2)
Affinity DataKd:  2.40E+3nMAssay Description:FGFR3: In a final reaction volume of 30 uL, FGFR3 (h) (40 ng/ml) is incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 4(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM588100(US11542247, Compound 2)
Affinity DataKd: >3.02E+3nMAssay Description:FGFR4: In a final reaction volume of 30 μL, FGFR4 (h) (60 ng/ml) is incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM588100(US11542247, Compound 2)
Affinity DataKd: >3.02E+3nMAssay Description:KDR (VEGFR2): In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) is incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM588101(US11542247, Compound 3)
Affinity DataKd:  331nMAssay Description:FGFR1: In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) is incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 2(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM588101(US11542247, Compound 3)
Affinity DataKd:  891nMAssay Description:FGFR2: In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) is incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.0...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 3(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM588101(US11542247, Compound 3)
Affinity DataKd:  537nMAssay Description:FGFR3: In a final reaction volume of 30 uL, FGFR3 (h) (40 ng/ml) is incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM588098(US11542247, Compound 1)
Affinity DataKd:  1.41E+3nMAssay Description:FGFR1: In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) is incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM588101(US11542247, Compound 3)
Affinity DataKd: >3.02E+3nMAssay Description:KDR (VEGFR2): In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) is incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM588103(US11542247, Compound 4)
Affinity DataKd: >3.02E+3nMAssay Description:FGFR1: In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) is incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 2(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM588103(US11542247, Compound 4)
Affinity DataKd: >3.02E+3nMAssay Description:FGFR2: In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) is incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.0...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 3(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM588103(US11542247, Compound 4)
Affinity DataKd: >3.02E+3nMAssay Description:FGFR3: In a final reaction volume of 30 uL, FGFR3 (h) (40 ng/ml) is incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 4(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM588103(US11542247, Compound 4)
Affinity DataKd: >3.02E+3nMAssay Description:FGFR4: In a final reaction volume of 30 μL, FGFR4 (h) (60 ng/ml) is incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM588103(US11542247, Compound 4)
Affinity DataKd: >3.02E+3nMAssay Description:KDR (VEGFR2): In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) is incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM588104(US11542247, Compound 5)
Affinity DataKd:  1.95E+3nMAssay Description:FGFR1: In a final reaction volume of 30 μL, FGFR1 (h) (25 ng/ml) is incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 2(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM588104(US11542247, Compound 5)
Affinity DataKd: >3.02E+3nMAssay Description:FGFR2: In a final reaction volume of 30 μL, FGFR2 (h) (150 ng/ml) is incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.0...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 3(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM588104(US11542247, Compound 5)
Affinity DataKd:  1.26E+3nMAssay Description:FGFR3: In a final reaction volume of 30 uL, FGFR3 (h) (40 ng/ml) is incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01% Tri...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetFibroblast growth factor receptor 4(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM588104(US11542247, Compound 5)
Affinity DataKd: >3.02E+3nMAssay Description:FGFR4: In a final reaction volume of 30 μL, FGFR4 (h) (60 ng/ml) is incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4, 0.01...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetVascular endothelial growth factor receptor 2(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM588104(US11542247, Compound 5)
Affinity DataKd: >3.02E+3nMAssay Description:KDR (VEGFR2): In a final reaction volume of 30 μL, KDR (h) (150 ng/ml) is incubated with 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.1 mM Na3VO4...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent